Bismuth for PCAB-based H. Pylori Eradication

Status Completed

Clinical Trial Summary

Tegoprazan is a new potassium-competitive acid blocker (PCAB) that has been clinically available since 2018 in South Korea. P-CAB is highly active drugs targeting H+, K+ -ATPase in the gastric acid secretion of parietal cells. The mechanism of action is different from that of PPIs. Conventional PPIs require 3-5 days to achieve maximal and steady-state gastric acid inhibition, whereas P-CAB increases the intragastric pH to nearly 7 within four hours. In Japan, H. pylori eradication success rates has increased by therapies using P-CAB than those using proton pump inhibitors, owing to the stronger acid suppression capability of P-CAB. Bismuth has long been used to treat peptic ulcer disease, dyspepsia, parasite infections, and infectious diarrhea. The antibacterial effects of bismuth include inhibition of protein and cell wall synthesis in H. pylori. The main role of bismuth is to increase the eradication rate by 30%-40% in resistant H. pylori strains.

Clinical Trial Description

The investigators aim to evaluate the success rate and adverse drug events of bismuth added to PCAB-based triple therapy as a first-line regimen for H. pylori infection. ;

Study Design

Related Conditions & MeSH terms

H. Pylori Infection

Clinical Trial Details

NCT number	NCT05453994
Study type	Observational
Source	Soonchunhyang University Hospital
Contact
Status	Completed
Phase
Start date	March 1, 2020
Completion date	August 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06045494` - The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21	N/A
Not yet recruiting	`NCT01449500` - Supplementation With L. Reuteri in H. Pylori Infected Adults	N/A
Completed	`NCT01234389` - Immediate Detection of Helicobacter Infection With a New Electrochemical System.	N/A
Not yet recruiting	`NCT05387005` - Screening Strategy for Gastric Cancer Prevention	N/A
Not yet recruiting	`NCT02761005` - Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori	Phase 2
Recruiting	`NCT03142620` - Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study	Phase 3
Withdrawn	`NCT02090738` - A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide	Phase 2
Recruiting	`NCT01335334` - H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study	Phase 4
Recruiting	`NCT05544396` - Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis.	N/A
Recruiting	`NCT04713670` - Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection	Phase 4
Recruiting	`NCT06045832` - Oral Helicobacter Pylori Eradication	N/A
Recruiting	`NCT02328131` - European Registry on the Management of Helicobacter Pylori Infection
Completed	`NCT00197457` - Pepsinogens as the Early Marker of H. Pylori Eradication	Phase 2
Not yet recruiting	`NCT06412640` - Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori	Phase 4
Completed	`NCT04036838` - ARJ C13 Urea Breath Test System	Phase 2
Completed	`NCT06050824` - A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection	Phase 4
Completed	`NCT02767479` - Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori	Phase 3
Completed	`NCT01505127` - Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori	Phase 3
Recruiting	`NCT05176821` - Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection	N/A
Completed	`NCT05002595` - H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy